Literature DB >> 12226555

Oxidized LDL antibodies (OLAB) in patients with beta-thalassemia major.

Patrizia Brizzi1, Teresa Isaja, Alfonsina D'Agata, Lucia Malaguarnera, Mariano Malaguarnera, Salvatore Musumeci.   

Abstract

Thalassemic (TM) patients are subjected to peroxidative tissue injury because of continuous blood transfusions. It has been documented that circulating LDL from TM patients show marked oxidative modification, that could represent an event leading to atherogenesis. We investigated in 75 beta-TM patients the levels of oxidized LDL antibody (OLAB) to asses their correlation with total cholesterol, LDL and HDL cholesterol, triglycerides Apo A-1 and Apo B. OLAB/mg chol-LDL is greater in TM patients than healthy controls (p<0.001). No correlation was found between OLAB and age, sex of patients, mean blood consumption, mean serum ferritin, mean transaminases, PT, PTT, and fibrinogen. A significant positive correlation was found between OLAB and triglycerides in TM patients (p<0.001). Also a significant correlation was found between OLAB/mg chol-LDL and level of triglycerides in TM patients, but not with total cholesterol, LDL and HDL chols, Apo A-1 and Apo B. On the contrary in the healthy controls this correlation between OLAB and OLAB/mg chol-LDL versus triglycerides was negative and not significant. High levels of OLAB/mg chol-LDL in patients with beta-thalassemia, in absence of evident signs of atherosclerosis, suggest some regulatory mechanisms on the lipid peroxidation which modulate the deposition of ox-LDL in the macrophages and support the hypothesis that both serum iron and triglycerides are involved in the pathogenesis of LDL oxidation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12226555     DOI: 10.5551/jat.9.139

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  6 in total

1.  Oxidative modification and poor protective activity of HDL on LDL oxidation in thalassemia.

Authors:  Supeenun Unchern; Narumon Laohareungpanya; Yupin Sanvarinda; Kovit Pattanapanyasat; Pansakorn Tanratana; Udom Chantharaksri; Nathawut Sibmooh
Journal:  Lipids       Date:  2010-06-09       Impact factor: 1.880

2.  Al-hijamah (the triple S treatment of prophetic medicine) exerts cardioprotective, tissue-protective and immune potentiating effects in thalassemic children: a pilot clinical trial.

Authors:  Mohamed El-Shanshory; Nahed Mohammed Hablas; Yasmin Shebel; Osama Alhadramy; Rehab El-Tahlawi; Moutasem Salih Aboonq; Tamer M Soliman; Abdelhady Ragab Abdel-Gawad; Sayed Mostafa El Sayed; Hesham I Abdallah; Hany Salah Mahmoud; Hassan El-Allaf; Samer El-Sawy; Reda S Yousef; Mostafa Abu-El Naga; Reham A Mariah; Manal Mohamed Helmy Nabo; Mohamed Abdel-Haleem; Ahmed Alamir Mahmoud; Mohammad Ahmad Hassan; Areej Hesham Al Arabi; Abdullah Ahmed Alnakhli; Salah Mohamed El Sayed
Journal:  Am J Blood Res       Date:  2020-12-15

3.  Association of Iron Overload with Oxidative Stress, Hepatic Damage and Dyslipidemia in Transfusion-Dependent β-Thalassemia/HbE Patients.

Authors:  Chintana Sengsuk; Orathai Tangvarasittichai; Prasert Chantanaskulwong; Ampai Pimanprom; Somsak Wantaneeyawong; Anuchit Choowet; Surapon Tangvarasittichai
Journal:  Indian J Clin Biochem       Date:  2013-08-29

Review 4.  Atherogenesis and iron: from epidemiology to cellular level.

Authors:  Francesca Vinchi; Martina U Muckenthaler; Milene C Da Silva; György Balla; József Balla; Viktória Jeney
Journal:  Front Pharmacol       Date:  2014-05-05       Impact factor: 5.810

Review 5.  Al-hijamah and oral honey for treating thalassemia, conditions of iron overload, and hyperferremia: toward improving the therapeutic outcomes.

Authors:  Salah Mohamed El Sayed; Hussam Baghdadi; Ashraf Abou-Taleb; Hany Salah Mahmoud; Reham A Maria; Nagwa S Ahmed; Manal Mohamed Helmy Nabo
Journal:  J Blood Med       Date:  2014-10-30

6.  Serum Lipids in Turkish Patients with β-Thalassemia Major and β-Thalassemia Minor.

Authors:  Yasemin Işık Balcı; Şule Ünal; Fatma Gümrük
Journal:  Turk J Haematol       Date:  2015-04-06       Impact factor: 1.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.